HBV HDV Vaccine Composition DNA Prime Protein Boost
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic hepatitis B and D infections are inadequate, with nucleoside analogues providing only lifelong suppression of viral replication and not eliminating the risk of cancer, and existing vaccines failing to establish prophylactic immunity against both infections.
Innovation Solution
The use of recombinant nucleic acids, DNA, RNA, proteins, polypeptides, or peptides comprising HBV and/or HDV antigens in a DNA prime/protein boost composition approach to induce immune responses, antibody production, and immunity against HBV and/or HDV infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogues are used for HBV therapy, then viral replication is suppressed, but the risk of cancer is not eliminated and lifelong treatment is required
Solution Approach 1:
The vaccine is administered before HBV infection occurs, establishing prophylactic immunity in advance. This preliminary action prevents the need for lifelong suppressive therapy by creating protective antibodies and T-cell responses that block viral entry and replication before infection can establish
Solution Approach 2:
The invention converts the harmful chronic infection state into a beneficial protective immune response. By using HBV antigens (PreS1, S, PreS2) as vaccine components, the harmful viral proteins are repurposed to stimulate protective immunity, transforming the pathogen's own structures into defensive tools
2Reliability
If existing vaccines are used, then some immune response is generated, but prophylactic immunity against both HBV and HDV is not established
Solution Approach 1:
The invention merges HBV antigens (PreS1, S, PreS2) with HDV antigen (HDAg) into a single combined vaccine composition. This merging strategy simultaneously targets both viruses, establishing cross-protective immunity against HBV and HDV coinfection or superinfection through a single immunization regimen
Solution Approach 2:
The vaccine composition is designed with multi-functionality to protect against multiple viral threats. The combination of HBV and HDV antigens creates a universal prophylactic that addresses both infections, which commonly occur together, providing broad-spectrum protection that exceeds single-virus vaccines
3Reliability
If DNA-only or protein-only immunogenic compositions are used, then immune response is induced, but the response is insufficient compared to combined approaches
Solution Approach 1:
The invention uses a composite immunogenic composition that combines DNA and protein components in a prime-boost strategy. The DNA prime induces initial antigen expression and immune cell activation, while the protein boost enhances antibody production and affinity maturation, creating a synergistic effect that produces superior immune responses compared to either component alone
Data Source
AI summary
Disclosed herein are immunogenic compositions or product combinations of engineered hepatitis B and hepatitis D nucleic acids, genes, peptides, or proteins that can be used to elicit an immune response against a hepatitis B and/or hepatitis D infection. Also disclosed are methods of using the immunogenic compositions or product combinations in subjects to generate immune responses against HBV and/or HDV by administering the compositions or combinations, for example, with a nucleic acid prime and polypeptide boost approach.